Please assess the completion status of the following clinical trial:

Trial Title: Study of Anti-r-HuEpo Associated Pure Red Cell Aplasia (PRCA) Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age more than 18 years old~* CKD patient with anti-r-huEpo associated PRCA~Exclusion Criteria:~* Pregnancy or lactating women~* Receiving immunosuppression~* Active infection~* Previous history of allergic reaction to cyclosporine, mycophenolate mofetil, cyclophosphamide, prednisolone

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- CSA+MMF (Type: ACTIVE_COMPARATOR): Cyclosporine 100 mg BID combine with Mycophenolate mofetil 750 mg BID for 24 weeks
- Cyclophosphamide + pred (Type: ACTIVE_COMPARATOR): Cyclophosphamide 100 mg QD and prednisolone 1.0 mg/kg/day

Based on this trial design, predict the completion outcome and termination type (if applicable).